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Background: To explore current status and choices regarding diagnosis and treatment of Parkinson’s disease (PD)
among physicians, general neurologists and movement disorders specialists in China via a national survey.
Methods: The cross-sectional questionnaire-based survey was conducted from November, 2010 to July, 2011. Six
hundreds and twelve doctors from different cities in China were recruited for this study.
Results: 68.6% (n=420) and 23.9% (n=146) of doctors have read the national and international guidelines,
respectively. There was a larger proportion of movement disorders specialists reading the guidelines, in contrast to
physicians and general neurologists (P<0.001). Up to 76.4% (n=465) and 81.8% (n=498) of doctors would choose
standard oral levodopa test and conventional MRI(with T1 and T2), respectively; Whereas susceptibility weighed
imaging(SWI)(16.1%; n=98), transcranial sonography (TCS) (1.8%; n=11) and functional neuroimaging test, such as
single photon emission computed tomography(SPECT) (10.2%; n=62) and positron emission tomography(PET)
(13.3%; n=81) were less used for suspected patients with PD in clinical practice. Doctors at different levels or from
different hospitals and cities would choose different medication for motor complications and non-motor symptoms
of patients with PD, in addition to initial drug selection for newly diagnosed PD. Doctors who had read the
guidelines had significantly better knowledge of medication selections for PD under specific circumstances.
Conclusions: Compared with commonly employed standard oral levodopa test and conventional MRI, SWI
complements MRI, TCS and functional neuroimaging were less performed for diagnosis of PD in clinical practice in
China. The choices of diagnostic methods and therapeutic strategy of PD vary among physicians, general
neurologists and movement disorders specialists. Guideline awareness is markedly beneficial to reasonable PD
medications strategy in China.
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Recently, epidemiological investigations indicated that
there were approximately at least two million patients
with Parkinson’s disease (PD) in China, accounting for
2/5 of the whole PD patients in the world [1]. Over the
past three decades, significant progresses have been
achieved on the diagnosis and treatment of PD in China.* Correspondence: wgneuron@hotmail.com; chen_sd@medmail.com.cn
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reproduction in any medium, provided the orSo far, the academic Chinese guidelines (First version
(2006) and updated version (2009)) on the treatment of
PD have been published by Chinese Parkinson’s Disease
& Movement Disorders Society (CPDMDS) in recent
years [2,3], respectively, soon after the dissemination of
the counterparts from American Academy of Neurology
(AAN) [4-7], European Federation of Neurological Soci-
eties (EFNS) and National Institute for Health and Clin-
ical Excellence (NICE) in the United Kingdom [8]. It
seems that the gap of diagnosis and management of PD
patients is narrowing between China and Westerntd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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opinions regarding diagnosis and treatment of PD
among Chinese doctors is unknown unfortunately [9]. It
is believed as a key influential factor to determine the
actual benefit for patients [10-13].
In China, in addition to movement disorders specia-
lists, both general neurologists and physicians are caring
for PD patients. Each province has one capital city (such
as Nanjing city as capital city of Jiangsu Province and
Guangzhou city as capital of Guangdong Province) with
integrated financial and economic centers. More medical
resources were distributed in a few tertiary class hospi-
tals in capital cities with over 1000 beds, followed by
secondary class hospitals mostly located in the county
with over 400 beds and primary health service centers
[14,15]. The movement disorders clinics and associated
centers only exist in part of tertiary hospitals, and the
resources could not satisfy the need of most patients
with PD. In many cases, both general neurologists and
physicians are taking the responsibility for diagnosis and
treatment of PD patients. Therefore, the opinions from
physicians, general neurologists and movement disorders
specialists in the clinical practice for PD will be diverse,
which will have significant influence on the actual bene-
fits of patients with PD.
Therein, we designed a national survey to investigate
the opinions regarding diagnostic approaches for sus-
pected PD, medications selection strategy for newly
diagnosed PD, and motor complications & non-motor
symptoms (NMSs) for follow-up patients among doctors
at different levels.
Methods
Survey setting and sample
The study was sponsored by Chinese Parkinson’s Disease
& Movement Disorders Society, Neurology Branch of
Chinese Medical Association. From November, 2010 to
July, 2011, questionnaires were randomly distributed to
doctors attending National Neurological Congress, sev-
eral Provincial Conferences or CME courses of PD held
in Beijing, Shanghai, Chongqing, Guangzhou, Zheng-
zhou, Nanning and Hangzhou, respectively. In this sur-
vey, we classified the congress participants into three
categories by their specialties and sub-specialties: A
movement disorders specialist is a neurologist who has
taken additional training in the subspecialty in neurology
called movement disorders (as compared to other sub-
specialties in neurology) and regularly attends the move-
ment disorders clinics; A neurologist who specializes in
general neurology rather than movement disorders, is
classified as general neurologists; Physicians are the doc-
tors who did not work in neurology department, includ-
ing general physicians and internal medicine specialists.
While family physicians were not included in this survey.All of the abovementioned three categories of doctors
had qualified medical licenses issued by the Chinese
Public Health Administration.
Finally, a total of 900 questionnaires were distributed,
768 questionnaires were returned (response rate 85.3%),
and 612 (effective rate 79.7%) questionnaires with
complete demographic data were available for further
evaluation (Figure 1). Of the 612 participants, 328
(53.6%) were male. 248(40.5%) were below 35 and 352
(57.5%) were 35–60 years old. 406(66.3%) responders
came from tertiary hospitals, only 181(29.6%) and 25
(4.1%) came from secondary hospitals and private
clinics. Majority of the participants were general neurol-
ogists (70.8%, n=433) rather than physicians (14.7%,
n=90) and movement disorder specialists (14.5%, n=89).
Questionnaire design
The questionnaire (Additional file 1) was designed by
three of the authors (Dr. Gang Wang, Dr. Wei Chen and
Dr. Sheng-Di Chen) with approval from the Research
Ethics Committee, Ruijin Hospital affiliated to Shanghai
Jiao Tong University School of Medicine, Shanghai,
China. It covered three sections: (1) Continuing Medical
Educations(CME) & research experiences for PD: con-
sisting of guideline reading, specialty information source,
CME activity frequency, PD patients to provide consult-
ation service monthly on average, research papers pub-
lished, etc.; (2) Initial diagnostic approaches for PD
patients: including choices of a standard oral levodopa
test, conventional magnetic resonance imaging (MRI),
susceptibility weighed imaging (SWI), transcranial son-
ography (TCS), single-photon emission computed tom-
ography (SPECT) and positron emission tomography
(PET), in addition to assessment of putative pre-motor
symptoms of PD; (3) Strategy on PD management: com-
prising of initial medications choices for newly diag-
nosed PD, how to deal with wearing-off phenomenon,
peak-dose dyskinesia, and some common non-motor
symptoms, including psychosis, dementia, depression
and restless legs syndrome. The response categories
were in multiple-choice format for easily completing. It
took about 20–30 min for finishing.
Statistical analysis
Statistical analysis was performed with SPSS, with stu-
dent’s t test for comparing group means and chi-squared
analysis for comparing proportions. The significance
level was set at P<0.05.
Results
CME & research experiences for PD
Of the 612 participants, 68.6% (n=420) and 23.9%
(n=146) have read the national and international guide-
lines, respectively. There was a larger proportion of
Figure 1 Screening strategy for questionnaires through the survey.
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the national guideline, in contrast to general neurologists
(302/433, 69.7%) and physicians (43/90, 47.8%)
(P<0.001). The situation was similar for the international
guidelines reading (51.7% for movement disorders spe-
cialists VS. 19.6% for general neurologists VS. 16.7% for
physicians; P<0.001). There were 72.9% (n=446) of
responders caring for below 10 PD patients each month;
17.8% (n=109) 10–30, and 5.4% (n=33) above 30 PD
patients monthly. However, 3.8% (n=23) of those have
never diagnosed and treated PD patients before, most of
whom are from secondary hospitals or private clinics.
There were more movement disorders specialists (48/89,
53.9%) caring for more than 10 PD patients each month,
than the general neurologists (90/433, 20.8%) and physi-
cians (4/90, 4.4%) (P<0.001).
From the survey, information with respect to the
current advances in PD was most frequently obtained
from lectures of movement disorders specialists (68.0%;
n=416), followed by professional journals (59.8%;
n=366), movement disorders textbooks (57.8%; n=354),
guidelines (50.8%; n=311) and information from the
pharmaceutical sales representatives (14.9%; n=91).
Regarding CME activity frequency for PD, 54.2%
(n=332) of participants attended once or twice every
year. Only 18.8% (n=115) took part in CME activities
more than 3 times each year. 26.1% (n=160) neverattended any programs before, which included 48.9%
(44/90) physicians, 25.1% (109/433) general neurologists,
and 7.9%(7/89) movement disorders specialists. With re-
spect to papers published for PD, up to 80.6% (n=493)
participants had never published any article. Only 17.1%
(n=105) and 9.5% (n=58) had published papers for clin-
ical studies and basic researches on PD, respectively.
There were 101 (16.5%) responders undertaking basic
research of PD at the same time of regular clinical works
at present.
Initial diagnostic approaches for PD
Most participants, 76.4% (n=465), would adopt standard
oral levodopa test as differential diagnosis method for
patients with suspected PD. Conventional cranial MRI
with T1 and T2 weighted images were performed by
81.8% (n=498) of those surveyed for diagnosis and differ-
ential diagnosis for PD. A small proportion of the
responders would take SWI (16.1%; n=98), TCS (1.8%;
n=11) and functional neuroimaging, such as SPECT
(10.2%; n=62) and PET (13.3%; n=81) for PD diagnosis.
As putative pre-motor symptoms of PD, hyposmia,
REM sleep behavior disorder(RBD), constipation, anxiety
& depression were separately recognized as regular as-
sessment items in the clinic by 42.5% (n=259), 43.5%
(n=265), 36.3% (n=221) and 41.7% (n=254) of partici-
pants. There were significant differences regarding
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symptoms including hyposmia, RBD and constipation
across the three doctor categories. Movement disorders
specialists had a relatively higher cognition for related
diagnostic methods (Table 1).
Strategy on PD management
Initial medications for newly diagnosed PD
With regard to initial medications for PD patients aged
below 65 years without cognitive impairments (CI),
dopamine agonists were employed by 42.9% (n=210) of
489 participants, followed by levodopa (33.5%) and
MAO-B inhibitors (12.7%). Meanwhile, levodopa was
used by 56.6% (n=277) of those surveyed for PD patients
aged above 65 years or with CI (Table 2).
Motor complications treatment
For patients with wearing-off phenomenon, the most
common therapeutic strategy was a switch from standard
levodopa to CR levodopa (48.3%; n=236) among those sur-
veyed. Additionally, enhancement of levodopa frequency
(38.2%; n=187) and usage of some additives, such as dopa-
mine agonists (40.1%, n=196) and COMT or MAO-B
inhibitors (41.5%, n=203) were also regularly employed;
44.6% (n=218) of participants would reduce levodopa dose
and add its frequency for patients with peak-dose dyskin-
esia, whereas only 14.5% (n=71) of those surveyed would
choose amantadine for such condition (Table 2).
Non-motor symptoms(NMSs) treatment
Regarding medication selection for frequent NMSs, over
45.8% of responders employed Olanzapine rather than
Clozapine (22.9%) for PD patients with psychosis. Mem-
antine, donepezil, rivastigmine, and huperzine A were







Levodopa test 465(76.4%) 49(53.8%)
Neuroimaging









Anxiety & depression 254(41.7%) 28(30.8%)16.8% (n=82), and 25.4% (n=124) of participants to im-
prove CI in PD patients. Selective serotonin reuptake
inhibitors (59.7%; n=292) were most popular agents for
selecting to treat depression symptoms of PD patients.
Only 20.7% and 37.8% of participants prefer to choose
tricyclic antidepressants and pramipexole to deal with
depression, respectively. Dopamine agonists, benzodiaze-
pines and levodopa were selected by 30.5%, 25.2% and
28.6% of participants to deal with restless legs syndrome,
respectively (Table 2).
There was a relatively high level of knowledge on
therapeutic strategy among movement disorders specia-
lists (Table 2) and those from tertiary hospitals and cap-
ital cities (Table 3). Doctors who had read the guidelines
had significantly better knowledge of medication selec-
tions for PD under specific circumstances (Table 4).
Discussion
This survey summarized general recognitions and opi-
nions on the diagnosis and treatment of PD since the
publication and dissemination of the first edition of
Chinese PD diagnosis criteria and treatment guideline in
China in 2006. With global populations aging, there are
more than two million PD patients in China by rough
estimation, accounting for 40% PD patients in the world,
which brings heavy economic burden to the communi-
ties and families [16]. Managing the large population of
PD patients in clinical practice and getting more and
more updated information from the movement disorders
specialists in the world, Chinese doctors have signifi-
cantly improved their ability to make diagnosis and carry
out reasonable therapy for PD over the past three dec-
ades. However, rare reports focus on medications selec-
tion strategy among professional levels of doctors in


























Age < 65 years without cognitive impairment
Levodopa 164(33.5%) 28(41.8%) 114(33.1%) 22(28.2%) 0.216
Dopamine agonists 210(42.9%) 13(19.4%) 144(41.9%) 53(67.9%) 0.000
MAO-B inhibitors 62(12.7%) 8(11.9%) 37(10.8%) 17(21.8%) 0.030
Age > 65 years or with cognitive impairment
Levodopa 277(56.6%) 30(44.8%) 192(55.8%) 55(70.5%) 0.007
Dopamine agonists 114(23.3%) 8(11.9%) 80(23.3%) 26(33.3%) 0.01
MAO-B inhibitors 41(8.4%) 7(10.4%) 26(7.6%) 8(10.3%) 0.597
Wearing-off phenomenon
Add levodopa frequency 187(38.2%) 14(20.9%) 131(38.1%) 42(53.8%) 0.000
Switch to CR levodopa 236(48.3%) 15(22.4%) 173(50.3%) 48(61.5%) 0.000
Add COMT inhibitors or MAO-B inhibitors 203(41.5%) 21(31.3%) 136(39.5%) 46(59.0%) 0.001
Add dopamine agonists 196(40.1%) 15(22.4%) 143(41.6%) 38(48.7%) 0.003
Peak-dose dyskinesia
Reduce levodopa dose, add its frequency 218(44.6%) 24(35.8%) 149(43.3%) 45(57.7%) 0.021
Reduce levodopa dose, add dopamine agonists 215(44.0%) 15(22.4%) 151(43.9%) 49(62.8%) 0.000
Reduce levodopa dose, add COMT inhibitors 145(29.7%) 15(22.4%) 97(28.2%) 33(42.3%) 0.018
Add amantadine 71(14.5%) 8(11.9%) 38(11.0%) 25(32.1%) 0.000
PD with psychosis
Clozapine 112(22.9%) 11(16.4%) 67(19.5%) 34(43.6%) 0.000
Olanzapine 224(45.8%) 27(40.3%) 162(47.1%) 35(44.9%) 0.584
Quetiapine 106(21.7%) 9(13.4%) 68(19.8%) 29(37.2%) 0.001
PD with dementia
Huperzine A 124(25.4%) 8(11.9%) 101(29.3%) 15(19.2%) 0.004
Donepezil 263(53.8%) 30(44.8%) 178(51.7%) 55(70.5%) 0.003
Rivastigmine 82(16.8%) 10(14.9%) 50(14.5%) 22(28.2%) 0.013
Memantine 185(37.8%) 15(22.4%) 126(36.6%) 44(56.4%) 0.000
PD with depression
Tricyclic antidepressants 101(20.7%) 13(19.4%) 79(23.0%) 9(11.5%) 0.077
SSRIs 292(59.7%) 31(46.3%) 200(58.1%) 61(78.2%) 0.000
Pramipexole 185(37.8%) 16(23.9%) 125(36.3%) 44(56.4%) 0.000
PD with RLS
Levodopa 123(25.2%) 11(16.4%) 86(25.0%) 26(33.3%) 0.064
Dopamine agonists 149(30.5%) 15(22.4%) 90(26.2%) 44(56.4%) 0.000
Benzodiazepines 140(28.6%) 15(22.4%) 108(31.4%) 17(21.8%) 0.114
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Countries, where only the movement disorders specialists
have the qualifications to provide consultations to the PD
patients referred from other doctors, both general neurol-
ogists and physicians are caring for PD patients in China,
in addition to movement disorders specialists. In fact, in
China neither the numbers of movement disorders clinics
nor the movement disorders specialists are sufficient to
cope with the increasing PD patients. These differences inour survey among doctors at different levels for PD clinics
may reflect at least two aspects: one is a relative shortage
of medical professional human resources of movement
disorders specialists in China, and the second is that the
corresponding subspecialty fellowship training programs
are lacking [14,15,18].
From the perspective of doctors, this survey displays
the general features on PD in China: most of the partici-
pants have adopted the Chinese PD guideline to instruct















Age < 65 years without cognitive impairment
Levodopa 60(40.8%) 104(30.4%) 0.025 102(39.4%) 62(27.0%) 0.004
Dopamine agonists 47(32.0%) 163(47.7%) 0.001 77(29.7%) 133(57.8%) 0.000
MAO-B inhibitors 15(10.2%) 47(13.7%) 0.282 22(8.5%) 40(17.4%) 0.003
Age > 65 years or with cognitive impairment
Levodopa 86(58.5%) 191(55.8%) 0.587 127(49.0%) 150(65.2%) 0.000
Dopamine agonists 17(11.6%) 97(28.4%) 0.000 45(17.4%) 69(30.0%) 0.001
MAO-B inhibitors 12(8.2%) 29(8.5%) 0.908 19(7.3%) 22(9.6%) 0.375
Wearing-off phenomenon
Add levodopa frequency 44(29.9%) 143(41.8%) 0.013 67(25.9%) 120(52.2%) 0.000
Switch to CR levodopa 67(45.6%) 169(49.4%) 0.436 106(40.9%) 130(56.5%) 0.001
Add COMT or MAO-B inhibitors 54(36.7%) 149(43.6%) 0.160 85(32.8%) 118(51.3%) 0.000
Add dopamine agonists 58(39.5%) 138(40.4%) 0.853 81(31.3%) 115(50.0%) 0.000
Peak-dose dyskinesia
Reduce levodopa dose, add its frequency 55(37.4%) 163(47.7%) 0.037 91(35.1%) 127(55.2%) 0.000
Reduce levodopa dose, add dopamine agonists 58(39.5%) 157(45.9%) 0.188 97(37.5%) 118(51.3%) 0.002
Reduce levodopa dose, add COMT inhibitors 41(27.9%) 104(30.4%) 0.576 60(23.2%) 85(37.0%) 0.001
Add amantadine 17(11.6%) 54(15.8%) 0.224 31(12.0%) 40(17.4%) 0.089
PD with psychosis
Clozapine 31(21.1%) 81(23.7%) 0.531 41(15.8%) 71(30.9%) 0.000
Olanzapine 59(40.1%) 165(48.2%) 0.099 98(37.8%) 126(54.8%) 0.000
Quetiapine 16(10.9%) 90(26.3%) 0.000 32(12.4%) 74(32.2%) 0.000
PD with dementia
Huperzine A 51(34.7%) 73(21.3%) 0.002 53(20.5%) 71(30.9%) 0.008
Donepezil 70(47.6%) 193(56.4%) 0.073 126(48.6%) 137(59.6%) 0.016
Rivastigmine 15(10.2%) 67(19.6%) 0.011 41(15.8%) 41(17.8%) 0.555
Memantine 32(21.8%) 153(44.7%) 0.000 61(23.6%) 124(53.9%) 0.000
PD with depression
Tricyclic antidepressants 41(27.9%) 60(17.5%) 0.010 65(25.1%) 36(15.7%) 0.010
SSRIs 86(58.5%) 206(60.2%) 0.721 144(55.6%) 148(64.3%) 0.049
Pramipexole 40(27.2%) 145(42.4%) 0.001 62(23.9%) 123(53.5%) 0.000
PD with RLS
Levodopa 31(21.1%) 92(26.9%) 0.174 48(18.5%) 75(32.6%) 0.000
Dopamine agonists 31(21.1%) 118(34.5%) 0.003 56(21.6%) 93(40.4%) 0.000
Benzodiazepines 43(29.3%) 97(28.4%) 0.842 88(34.0%) 52(22.6%) 0.006
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quency are very low and few of those surveyed have
published PD related articles. The phenomenon reflected
marked shortcomings of academic summary in routine
clinical works among most of the surveyed, especially
general neurologists and physicians. These pitfalls partly
explained the reasons for shortage of influential multi-center clinical studies and original basic research for PD
in China compared to Western countries and Japan.
With respect to diagnostic methods for PD, standard
oral levodopa test and conventional MRI were commonly
considered for suspected patients in routine practice,
whereas SWI, TCS and functional neuroimaging were
less referred. In China, relatively expensive functional
Table 4 The impact of PD guideline awareness on drug selection strategy under specific circumstances
Items Haven’t read the PD guideline(s)
(n=97)
Have read the PD guideline(s)
(n=392)
P value
Age < 65 years without cognitive impairment
Levodopa 44(45.4%) 120(30.6%) 0.006
Dopamine agonists 25(25.8%) 185(47.2%) 0.000
MAO-B inhibitors 7(7.2%) 55(14.0%) 0.071
Age > 65 years or with cognitive impairment
Levodopa 58(59.8%) 219(55.9%) 0.485
Dopamine agonists 17(17.5%) 97(24.7%) 0.132
MAO-B inhibitors 7(7.2%) 34(8.7%) 0.643
Wearing-off phenomenon
Add levodopa dose 30(30.9%) 157(40.1%) 0.098
Switch from standard levodopa to CR levodopa 31(32.0%) 205(52.3%) 0.000
Add COMT inhibitors or MAO-B inhibitors 21(21.6%) 182(46.4%) 0.000
Add dopamine agonists 20(20.6%) 176(44.9%) 0.000
Peak-dose dyskinesia
Reduce levodopa dose, add its frequency 41(42.3% ) 177(45.2%) 0.609
Reduce levodopa dose, add dopamine agonists 31(32.0% ) 184(46.9%) 0.008
Reduce levodopa dose, add COMT inhibitors 14(14.4%) 131(33.4%) 0.000
Add amantadine 9(9.3%) 62(15.8%) 0.102
PD with psychosis
Clozapine 17(17.5%) 95(24.2%) 0.159
Olanzapine 42(43.3%) 182(46.4%) 0.580
Quetiapine 14(14.4%) 92(23.5%) 0.053
PD with dementia
Huperzine A 26(26.8%) 98(25.0%) 0.715
Donepezil 51(52.6%) 212(54.1%) 0.790
Rivastigmine 8(8.2%) 74(18.9%) 0.012
Memantine 26(26.8%) 159(40.6%) 0.012
PD with depression
Tricyclic antidepressants 28(28.9%) 73(18.6%) 0.026
SSRIs 45(46.4%) 247(63.0%) 0.003
Pramipexole 20(20.6%) 165(42.1%) 0.000
PD with RLS
Levodopa 19(19.6%) 104(26.5%) 0.158
Dopamine agonists 20(20.6%) 129(32.9%) 0.019
Benzodiazepines 29(29.9%) 111(28.3%) 0.758
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http://www.biomedcentral.com/1471-2377/12/155neuroimaging methods, such as SPECT and PET are not
covered by Chinese medical insurances, and few patients
would like to choose them. Additionally, for loss of
knowledge and shortage of TCS experts in many hospi-
tals, TCS is rarely accepted as a regular method. During
the past few years, accumulating cross-sectional and lon-
gitudinal studies across the globe indicated that several
putative clinical symptoms, including hyposmia [19],
RBD [20], constipation [21], depression [22], might assistthe early diagnosis and differential diagnosis for PD. In
this survey, nearly 40% of those participants would use
aforementioned non-motor symptoms as assistant infor-
mation in the diagnosis and differential diagnosis for PD
in clinical practice. Meanwhile, the difference is signifi-
cant among different stratified doctors, except anxiety
and depression. More studies on pre-motor symptoms
are warranted to compare the sensitivity and specificity
of each non-motor symptom.
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gists and movement disorders specialists, Table 2),
work places (the hospitals and the located cities,
Table 3), and the Guideline awareness (Table 4) play
important roles for reasonable PD medications selec-
tion strategy. There was a relatively high level of
knowledge on therapeutic strategy under specific cir-
cumstance among movement disorders specialists and
those from tertiary hospitals. However, the discrepancy
between the guideline and clinical practice still exists
on management of non-motor symptoms among all of
those surveyed: Up to 45.8% of responders selected
olanzapine to treat PD patients with psychosis, only
22.9% of those prescribed clozapine. The most often
prescribed was donepezil, not rivastigmine, for PD with
dementia, etc. Based on those observations, great
efforts should be made to take the CME programs for
physicians and general neurologists. Popularization ac-
tivities of PD guideline across the country may be a
visible strategy to obtain such purpose. In addition to
establishment of clinical fellowship training system, the
birth and development of movement disorders clinic
team are necessary to standardize the diagnosis and
treatment of PD. Interdisciplinary communication and
cooperation among physicians, general neurologists
and movement disorders specialists are warranted to
optimize the management of PD, especially for late
stage patients with PD.
However, there are some limitations in this survey. As
an on-the-spot investigation, the questionnaire was dis-
tributed at various conferences and CME courses. There
was a potential selection bias as these meetings atten-
dants were likely more academic active compared to
those absentees. Additionally, there are rare studies for
cognition and attitude of expertise in the public health
populations in China so far. Therefore, a series of inves-
tigations focused on the expertise and CME will be pro-
moted on a large scale in the future.Conclusions
The national survey revealed that SWI complements
MRI, TCS and functional neuroimaging were less per-
formed for diagnosis of PD in clinical practice in China
compared with commonly employed standard oral levo-
dopa test and conventional MRI. The choices of diag-
nostic methods and therapeutic strategy of PD vary
among physicians, general neurologists and movement
disorders specialists. Guideline awareness is markedly
beneficial to reasonable PD medications strategy in
China. Further CME programs on the diagnosis and
management of PD patients are warranted especially for
physicians and general neurologists caring for PD
patients in China.Additional file
Additional file 1: Clinical practice for Parkinson’s disease (PD): A
questionnaire among Chinese doctors (English version).
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